Document is current
Any future updates will be listed below
-
Authors
He, Shan
Tan, Yukun
Ye, Qing
M Gubin, Matthew
Dede, Merve
Rafei, Hind
Peng, Weiyi
Rezvani, Katayoun
Mohanty, Vakul
Chen, Ken
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR190017)
National Cancer Institute (R01CA282027)
National Cancer Institute (5U01CA281902)
Chan Zuckerberg Initiative (2024-345892)
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 27 November 2025
First Online: 27 January 2026
Competing interests
: H.R. and K.R. from the University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical. K.R. from the University of Texas MD Anderson Cancer Center has an institutional financial conflict of interest with Affimed GmbH. K.R. participates on the Scientific Advisory Board for Avenge Bio, Virogin Biotech, Navan Technologies, Caribou Biosciences, Bit Bio Limited, Replay Holdings, oNKo Innate, and The Alliance for Cancer Gene Therapy ACGT. K.R. is the Scientific founder of Syena.
